News
DERM
3.720
-3.63%
-0.140
Weekly Report: what happened at DERM last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at DERM last week (0401-0405)?
Weekly Report · 04/08 10:31
Weekly Report: what happened at DERM last week (0325-0329)?
Weekly Report · 04/01 10:30
Journey Medical And 2 Other Stocks Under $4 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Retractable Technologies, Inc. President and CEO acquired a total of 5,096 shares an average price of $1.18. The Dow Jones index closed higher by over 475 points on Wednesday.
Benzinga · 03/28 11:14
VERI, CHEK and MESO are among pre market gainers
VERI, CHEK and MESO are among pre market gainers. Mesoblast (MESO) and Cazoo Group (CZOO) are among the biggest pre market losers. Krispy Kreme and AirNet Technology are also on the move.
Seeking Alpha · 03/27 12:24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Westport Fuel Systems Inc. (NASDAQ:WPRT) posts wider-than-expected fourth-quarter loss. Krispy Kreme, Inc. And McDonald's expanded their partnership. Stoke Therapeutics, Inc., shares gained 72.6% to $11.24. C3is Inc. Reported a year-over-year increase in financial results.
Benzinga · 03/26 17:45
12 Health Care Stocks Moving In Tuesday's Intraday Session
Stoke Therapeutics (NASDAQ:STOK) stock moved upwards by 71.8% to $11.16 during Tuesday's regular session. The company's, Q4 earnings came out 3 days ago. Mesoblast and OpGen shares also moved upwards.
Benzinga · 03/26 17:31
Weekly Report: what happened at DERM last week (0318-0322)?
Weekly Report · 03/25 10:32
Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers
Healthcare On the Move: Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers. S&P 500 Health Care Sector +0.23% to 1703.09. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/22 14:00
Recap: Journey Medical Q4 Earnings
Journey Medical reported its Q4 earnings of $0.03 on Thursday. Journey Medical beat estimates by 138.0%. The company's revenue was down $709 thousand from the same period last year. The company is expected to report its earnings on March 21, 2024.
Benzinga · 03/21 21:05
Journey Medical Q4 2023 Adj EPS $0.03 Beats $(0.08) Estimate, Sales $15.257M Beat $15.061M Estimate
Journey Medical reported quarterly earnings of $0.03 per share. The company reported quarterly sales of $15.257 million. Journey Medical beat the analyst consensus estimate by 137.5%. The company's sales for the quarter were down 4.44 percent from the same period last year.
Benzinga · 03/21 21:03
Journey Medical Corp reports results for the quarter ended in December - Earnings Summary
Journey Medical Corp reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 12 cents per share. Revenue fell 4.4% to $15.26 million from a year ago. Journey Medical Corp shares had fallen by 33.3% this quarter.
Reuters · 03/21 21:01
Journey Medical GAAP EPS of -$0.21 misses by $0.02, revenue of $79.18M beats by $0.21M
Journey Medical Corporation's FY GAAP EPS of -$0.21 misses by $0.02, revenue of $79.18M beats by $ 0.21M. Journey Medical's Q1 results were better than expected. The company's revenue was up 7.5% from the same quarter last year.
Seeking Alpha · 03/21 20:04
Press Release: Journey Medical Corporation -3-
The Company's net loss per common share is $0.21 for the quarter. The Company has included certain non-GAAP measures in this press release. The Company's operating expenses include the cost of goods sold and the impairment of intangible assets. The company has a net loss of $18.2 million.
Dow Jones · 03/21 20:01
Press Release: Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022. New Drug Application for rosacea treatment candidate DFD-29 accepted for U.S. FDA review; PDUFA goal date of November 4, 2024. Company to hold conference call today at 4:30 p.m. ET.
Dow Jones · 03/21 20:01
Earnings Scheduled For March 21, 2024
Creative Realities is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Welltower is likely to report earnings for its fourth quarter. Accenture is also projected to report before the bell. Other companies expected to be reporting before the Bell include Shoe Carnival, Y.M.C. And Y.T.
Benzinga · 03/21 10:15
Journey Medical FY Earnings Preview
Journey Medical Corporation (DERM) is scheduled to announce FY earnings results on Thursday, March 21st. The consensus EPS Estimate is -$0.19 and the consensus revenue estimate is $78.97M. Over the last 2 years, DERM has beaten EPS estimates 13% of the time.
Seeking Alpha · 03/20 21:35
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include: NIKE, FedEx and Lululemon Athletica. Other major earnings slated for release after Thursday's close include: AAR Corp. And Asensus Surgical. For the full earnings season calendar, click here.
Seeking Alpha · 03/20 21:35
Journey Medical Earnings Preview
Journey Medical is set to give its latest quarterly earnings report on Thursday. Analysts estimate the company will report an earnings per share of $-0.08. Last quarter the company beat EPS by $1.14. Shares of Journey Medical were trading at $3.79 as of March 19.
Benzinga · 03/20 17:01
Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment
Healthcare Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment. The FDA has set a goal date of November 4, 2024 for the approval of DFD-29 for the treatment of inflammatory lesions and erythema of rosace. Journey Medical Corporation (NASDAQ:DERM)
Seeking Alpha · 03/18 13:17
More
Webull provides a variety of real-time DERM stock news. You can receive the latest news about Journey Medical Corp through multiple platforms. This information may help you make smarter investment decisions.
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.